Long-term consequences of osteoporosis therapy with bisphosphonates
https://doi.org/10.14341/osteo13148
Abstract
Bisphosphonates (BPs) are medications widely used in clinical practice to treat osteoporosis (OP) and reduce fragility fractures. The extended use of antiresorptive therapy has drawn attention to two extremely rare, although severe, adverse events. Аtypical femoral fracture (AFF) and medication-related osteonecrosis of the jaw (MRONJ) are more common in patients with high cumulative doses and longer duration of therapy. The risk of AFF depends on the duration of treatment and is significantly increased among patients receiving BPs for more than 8 years. The risk may decrease and return to the initial level with discontinuation of BPs, it decreases by more than 50% during one year after the discontinuation. The risk of MRONJ is less dependent on the duration of therapy, it occurs more often in patients with cancer who are receiving higher cumulative doses of BPs. The combination of local trauma, microbial contamination and concomitant diseases induces this condition in patients with OP who are receiving BPs. BPs have demonstrated safety and effectiveness throughout the years and evidenced increased BMD and reduced fracture risks, and these benefits overweight the risks of rare adverse events.
About the Author
O. A. Nikitinskaya
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Oksana A. Nikitinskaya - MD, PhD.
115522, Kashirskoye shosse 34 A, Moscow
Researcher ID AAF-2616-2021, Scopus Author ID 6504217119
Competing Interests:
None
References
1. Compston J. Practical guidance for the use of bisphosphonates in osteoporosis. Bone. 2020; 136:115330. doi: https://doi.org/10.1016/j.bone.2020.115330
2. Belaya ZE, Belova Kyu. Biryukova EV, Dedov II, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and bone diseases. 2021;24(2):4-47. (In Russ.) doi: https://doi.org/10.14341/osteo12930
3. Black DM, Abrahamsen B, Bouxsein ML, et al. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333-368. doi: https://doi.org/10.1210/er.2018-00001
4. Ayers C, Kansagara D, Lazur B, et al. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):182-195. doi: https://doi.org/10.7326/M22-0684
5. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301. doi: https://doi.org/10.1210/jc.2004-0952
6. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94
7. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23
8. Khow KS, Shibu P, Yu SC, Chehade MJ, Visvanathan R. Epidemiology and Postoperative Outcomes of Atypical Femoral Fractures in Older Adults: A Systematic Review. J Nutr Health Aging. 2017; 21:83–91. doi: https://doi.org/10.1007/s12603-015-0652-3.2016/12/22
9. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012 Dec;27(12):2544-50. doi: https://doi.org/10.1002/jbmr.1719
10. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020; 383:743-53. doi: https://doi.org/10.1056/NEJMoa1916525
11. Pearce O, Edwards T, Al-Hourani K, Kelly M, Riddick A. Evaluation and management of atypical femoral fractures: an update of current knowledge. Eur J Orthop Surg Traumatol. 2021;31:825–840. doi: https://doi.org/10.1007/s00590-021-02896-3
12. Lloyd AA, Gludovatz B, Riedel C, et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci. 2017;114(33):8722–7. doi: https://doi.org/10.1073/pnas.1704460114
13. Farlay D, Rizzo S, Ste-Marie LG, Michou L, et al. Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. J Bone Miner Res. 2021 Jun;36(6):1031-1041. doi: https://doi.org/10.1002/jbmr.4244
14. Morin SN, Wall M, Belzile EL, et al. Assessment of femur geometrical parameters using EOS™ imaging technology in patients with atypical femur fractures; preliminary results. Bone. 2016; 83:184–9. doi: https://doi.org/10.1016/j.bone.2015.10.016
15. Tsuchie H, Miyakoshi N, Kasukawa Y, et al. Evaluation of the Nature and Etiologies of Risk Factors for Diaphyseal Atypical Femoral Fractures. Med Princ Pract. 2021;30(5):430-436. doi: https://doi.org/10.1159/000517484. doi: 10.1159/000517484
16. Pearce O, Edwards T, Al-Hourani K, et al. Evaluation and management of atypical femoral fractures: an update of current knowledge. Eur J Orthop Surg Traumatol. 2021;31:825–840. doi: https://doi.org/10.1007/s00590-021-02896-3
17. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100‐107. doi: https://doi.org/10.3109/17453674.2015.1004149
18. Roca-Ayats N, Balcells S, Garcia-Giralt N, et al. GGPS1 mutation and atypical femoral fractures with bisphosphonates. N Engl J Med. 2017;376(18):1794–5. doi: https://doi.org/10.1056/NEJMc1612804
19. Pérez-Núñez I, Pérez-Castrillón JL, Zarrabeitia MT, et al. Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. Mol Cell Biochem. 2015;409(1):45–50. doi: https://doi.org/10.1007/s11010-015-2510-3
20. Zhou W, van Rooij JGJ, Ebeling PR, et al. The Genetics of Atypical Femur Fractures-a Systematic Review. Curr Osteoporos Rep. 2021 Apr;19(2):123-130. doi: https://doi.org/10.1007/s11914-021-00658-y
21. Anastasilakis AD, Pepe J, Napoli N, et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1441-1460. doi: https://doi.org/10.1210/clinem/dgab888
22. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws AAoO and Maxillofacial S. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007 Mar;65(3):369-76. doi: https://doi.org/10.1016/j.joms.2006.11.003
23. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008 Dec;19(12):2091-2. doi: https://doi.org/10.1093/annonc/mdn653
24. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg. 2022 May;80(5):920-943. doi: https://doi.org/10.1016/j.joms.2022.02.008
25. Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27(2):383-394. doi: https://doi.org/10.1007/s00520-018-4501-x
26. Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020;25(1):e71-e83. doi: https://doi.org/10.4317/medoral.23191
27. Pabst AM, Ziebart T, Koch FP, et al. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes-- in vitro study. Clin Oral Investig. 2012 Feb;16(1):87-93. doi: https://doi.org/10.1007/s00784-010-0507-6
28. Kobayashi Y, Hiraga T, Ueda A, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2010 Mar;28(2):165-75. doi: https://doi.org/10.1007/s00774-009-0128-9
29. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007 Sep;41(3):318-20. doi: https://doi.org/10.1016/j.bone.2007.04.196
30. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. https://doi.org/. 2007 Aug 1;13(15 Pt 1):4482-6. doi: https://doi.org/10.1158/1078-0432.CCR-07-0551
31. Khan AA, Morrison A, Kendler DL, et al.; International Task Force on Osteonecrosis of the Jaw. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom. 2017;20(1):8-24. doi: https://doi.org/10.1016/j.jocd.2016.09.005
32. Khosla S, Burr D, Cauley J, et al. Bisphosphonate‐associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479‐1491. doi: https://doi.org/10.1359/jbmr.0707onj
33. Fuggle NR, Curtis B, Clynes M, et al. The treatment gap: The missed opportunities for osteoporosis therapy. Bone. 2021 Mar; 144:115833. doi: https://doi.org/10.1016/j.bone.2020.115833
34. Amigues C, Fresse A, Roux CH, et al. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Aalysis of the French Pharmacovigilance Database. Joint Bone Spine. 2023 Jun 2;90(6):105599. doi: https://doi.org/10.1016/j.jbspin.2023.105599
35. Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb;68(2):243-53. doi: https://doi.org/10.1016/j.joms.2009.03.050
36. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015; 30:934–944. doi: https://doi.org/10.1002/jbmr.2442
37. Fusco V, Cabras M, Erovigni F, et al. A multicenter observational study on medication-related osteonecrosis of the jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. Med Oral Patol Oral Cir Bucal. 2021;26(4):e466-e473. doi: https://doi.org/10.4317/medoral.24318
Review
For citations:
Nikitinskaya O.A. Long-term consequences of osteoporosis therapy with bisphosphonates. Osteoporosis and Bone Diseases. 2023;26(4):14-19. (In Russ.) https://doi.org/10.14341/osteo13148
Views:
1408
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
